Clinical Hub Aberystwyth
Your Health Matters
Novel Technologies for Diagnosing and Monitoring Pulmonary Diseases
IRAS ID 187325
Novel Technologies is a collaborative study between academia and the NHS. It uses the latest scientific advances to improve care for patients with a range of respiratory diseases.
We are grateful to the many patients who have taken part, and who continue to take part, in this study. Thank you.
This page shows how your contribution is helping to drive important clinical advances, and gives you a way to contact us if you wish.
Novel Technologies Launch Meeting, April 2016
Top row, left to right: Dr. Subhamay Ghosh, Prof. Luis Mur (Scientific Lead), Prof. Keir Lewis (Clinical Lead), Denisa Asandei, Adrian Mironas and Dr. Priya Sai-Giridhar
Bottom row, left to right: Dr. Tim Asibey-Berko, Dr. Kirsty Hett and Rachel Paes de Araujo
Our Research
Launched in April 2016, the Novel Technologies study looks for important changes in saliva, sputum, serum and pleural fluid that are linked to:
-
The presence of lung cancer
-
The stage of lung cancer
-
The type of lung cancer, for example non small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
-
COPD disease status and the triggers of exacerbations (flare ups when breathing becomes markedly worse)
-
Guiding the treatment of sleep apnoea
Meet the Novel Technologies Team
Chief Investigator
Prof. Keir Lewis
Keir Lewis is a Professor at Swansea University, Medical Director of Respiratory Innovation Wales and a Consultant in Respiratory Medicine at Hywel Dda University Health Board. As Clinical Lead for Novel Technologies, he helps shape new questions on biomarkers and identifies and recruits patients with a range of lung conditions.
_edited.jpg)
Respiratory Research Assistant
Sarah Bowen
Sarah is a Respiratory Research Assistant at Prince Philip Hospital, Hywel Dda University Health Board. She provides day to day administrative support for the project, maintains the site file and coordinates sample transfers.
Principal Investigator
Prof. Luis Mur
Prof. Mur is based at Aberystwyth University and is the Scientific Lead for Novel Technologies. He uses the latest 'omic approaches to understand a range of diseases. He is a Visiting Professor at UNESP (São Paulo) in Brazil, the University of Silesia in Poland and Northwest University in China, and holds recognised foreign expert status at Shandong University, China.
MD Researcher
Dr. Scott O'Rourke
Scott is researching for his MD, focusing on the biochemical changes in blood that occur with sleep apnoea and its treatment.
PhD Researcher
Tina Kramaric
Tina is using metabolomics (wide ranging biochemical analyses) to help diagnose a range of respiratory diseases, including lung cancer and COPD.
MPhil Researcher
Andrine Vangberg
Andrine is working to identify biochemical changes in urine that are linked to lung cancer, including its stage and type.
Publications
T Kramarić, RP de Araujo, K Love, T Asibey-Berko, S Ghosh, KE Lewis, LAJ Mur. (2022) Systemic changes in monoacylglycerols could be an indicator of inflammation in chronic obstructive pulmonary disease (COPD) patients Thorax 77 (Suppl 1), A90-A91
O’Rourke, S.; Thomas, S.; Lewis, C.; Bowen, S.; Mur, L.; Lewis, K. 13 (2021) The effect of continuous positive airway pressure (CPAP) on key plasma metabolites identifying obstructive sleep apnoea hypopnoea syndrome (OSAHS). BMJ Open Respiratory Research 2021, 8, A6-A7, doi:10.1136/bmjresp-2021-bssconf.11.
Wolffs, K.L.; Mansfield, B.; Bruce, R.T.; Huang, P.; Schepelmann, M.; Brennan, S.C.; Verckist, L.; Adriaensen, D.; De Araújo, R.P.; Mur, L.A.J., et al. Calcium-sensing receptor antagonism as a novel therapeutic for pulmonary fibrosis. medRxiv 2020, 10.1101/2020.03.12.20034751, 2020.2003.2012.20034751, doi:10.1101/2020.03.12.20034751.
Mansfield, B.; Ho, T.-R.; Mudway, I.; Lugg, S.T.; Corrigan, C.J.; Ward, J.P.T.; Thickett, D.; Prytherch, Z.; Scofield, S.; Kemp, P.J., et al. Calcium-sensing receptor antagonists, calcilytics, prevent activation of human dendritic and epithelial cells by urban particulate matter. European Respiratory Journal 2020, 56, 1970, doi:10.1183/13993003.congress-2020.1970.
Kramarić, T.; Thomas, S.; Love, K.; Bond, I.; Rooke, D.; Mur, L.; Lewis, K. Late Breaking Abstract - Early exploratory use of omic approaches to assess metabolite changes in COPD. European Respiratory Journal 2020, 56, 322, doi:10.1183/13993003.congress-2020.322.
Paes de Araujo, R.; Bertoni, N.; Seneda, A.L.; Felix, T.F.; Carvalho, M.; Lewis, K.E.; Hasimoto, E.N.; Beckmann, M.; Drigo, S.A.; Reis, P.P., et al. Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma. Metabolites 2019, 9, doi:10.3390/metabo9030047.
Mansfield, B.; Huang, P.; Bruce, R.; Ho, T.-R.; Du, X.; Huang, Q.; Wang, W.; Lugg, S.; Ford, W.; Kidd, E., et al. T4 Calcium-sensing receptor antagonists (calcilytics) as a novel therapeutic for alarmin-driven inflammatory lung disease. Thorax 2019, 74, A2-A3, doi:10.1136/thorax-2019-BTSabstracts2019.4.
Mur, L.; Mironas, A.; Paes, R.; O'Shea, K.; Lewis, K. Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases. European Respiratory Journal 2017, 50, PA375, doi:10.1183/1393003.congress-2017.PA375.